The MEK inhibitor selumetinib in combination with the third-generation EGFR tyrosine kinase inhibitor osmertinib has been evaluated, in parallel with the combinations of osimertinib plus savolitinib (MET inhibitor) or osimertinib plus durvalumab (anti-PD-L1 antibody), in a clinical trial investigating strategies to overcome EGFR inhibitor resistance (NCT02143466), in the context of EFGR-mutant NSCLC [98]. Here, MAP2K7 is linked to non-small cell lung carcinoma.